CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Dosing and Timing of Immuno-Oncology Drugs

Last updated: November 21, 2019
Project Number: HO0008-000
Product Line: Optimal Use, Technology Review
Result type: Report

Immuno-oncology (IO) drugs (also called immune checkpoint inhibitors or immunotherapy drugs) have transformed the field of cancer. These drugs have elicited unprecedented therapeutic responses, allowing significant regression and sometimes resolution of several cancer types. Dosing of IO therapies investigated in clinical trials is inconsistent across studies. Decision-makers are looking for evidence that would help improve the consistency of dosing schedules across tumour types. In addition, they are asking about the feasibility and timing of re-treatment with IO drugs after progression on IO-based adjuvant therapy. This review explores the clinical and pharmacological literature addressing these questions.